AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1 billion deal to buy ImmunoGen and its marketed ovarian cancer drug.

Even more alarming is AbbVie's payout ratio of 216.7%, far surpassing the peer average of 141%. This sky-high figure means ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

AbbVie is also looking at inorganic growth. After its acquisition of Allergan in 2020, it acquired ImmunoGen for $10.1 billion this year, giving it rights to Elahere — an ovarian cancer ...

In 2022, the global oncology market was valued at approximately $203.42 billion and is expected to reach over $470.61 billion ...

We recently published a list of 10 Best Big-Name Stocks to Buy Right Now According to Short Sellers. In this article, we are ...

AbbVie is also looking at inorganic growth. After its acquisition of Allergan in 2020, it acquired ImmunoGen for $10.1 billion this year, giving it rights to Elahere — an ovarian cancer ...

Given its better valuation, we believe that Pfizer stock (NYSE: PFE) is currently a better pick than its industry peer – AbbVie stock (NYSE:ABBV). PFE stock trades at a much lower multiple of 11x ...

In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target of $209.00. The company’s shares closed ...

Finally, AbbVie continues making strategic acquisitions, such as the recent pickup of ImmunoGen and its commercial ... but I only buy it when the dividend yield nears 4%. AbbVie is a terrific ...